Ware Lab

Smart, LR; Ambrose, EE; Balyorugulu, G; Songoro, P; Shabani, I; Komba, P; Charles, M; Howard, TA; McElhinney, KE; O'Hara, SM; et al. Stroke Prevention with Hydroxyurea Enabled through Research and Education (SPHERE): a Phase 2 primary stroke prevention trial in sub-Saharan Africa. Acta Haematologica. 2022.

Power-Hays, A; Dandoy, CE; Lorts, A; Perentesis, JP; Unaka, N; Ware, RE; McGann, PT. US News & World Report and quality metrics: Inclusion of sickle cell disease is a matter of equity. Pediatric Blood and Cancer. 2022; 69.

Quinn, CT; Ware, RE. New therapeutics for children with sickle cell disease: A time for celebration, caution, or both?. Pediatric Blood and Cancer. 2022; 69.

Macharia, AW; Mochamah, G; Makale, J; Howard, T; Mturi, N; Olupot-Olupot, P; Färnert, A; Ware, RE; Williams, TN. Case Report: β-thalassemia major on the East African coast. Wellcome Open Research. 2022; 7.

Nima, MK; Mukherjee, A; Sazed, SA; Hossainey, MR H; Phru, CS; Johora, FT; Safeukui, I; Saha, A; Khan, AA; Marma, AS P; et al. Assessment of Plasmodium falciparum Artemisinin Resistance Independent of kelch13 Polymorphisms and with Escalating Malaria in Bangladesh. mBio. 2022.

Quinn, CT; Ware, RE. Reproductive equity: preserve the reserve. Blood. 2022; 139:963-965.

Henrici, RC; Sautter, CL; Bond, C; Opoka, RO; Namazzi, R; Datta, D; Ware, RE; Conroy, AL; John, CC. Decreased parasite burden and altered host response in children with sickle cell anemia and severe anemia with malaria. Blood Advances. 2021; 5:4710-4720.

Rankine-Mullings, A; Reid, M; Soares, D; Taylor-Bryan, C; Wisdom-Phipps, M; Aldred, K; Latham, T; Schultz, WH; Knight-Madden, J; Badaloo, A; et al. Hydroxycarbamide treatment reduces transcranial Doppler velocity in the absence of transfusion support in children with sickle cell anaemia, elevated transcranial Doppler velocity, and cerebral vasculopathy: the EXTEND trial. British Journal of Haematology. 2021; 195:612-620.

Quinn, CT; Ware, RE. Increased oxygen affinity: to have and to hold. Blood. 2021; 138:1094-1095.

Sadaf, A; Ware, RE. Microscope diagnosis of MYH9-related thrombocytopenia. Blood. 2021; 138.

Sadaf, A; Quinn, CT; Korpik, JB; Pfeiffer, A; Reynaud, M; Niss, O; Malik, P; Ware, RE; Kalfa, TA; McGann, PT. Rapid and automated quantitation of dense red blood cells: A robust biomarker of hydroxyurea treatment response. Blood Cells, Molecules, and Diseases. 2021; 90.

Pecker, LH; Sharma, D; Nero, A; Paidas, MJ; Ware, RE; James, AH; Smith-Whitley, K. Knowledge gaps in reproductive and sexual health in girls and women with sickle cell disease. British Journal of Haematology. 2021; 194:970-979.

Hernandez, AG; Kiyaga, C; Howard, TA; Ssewanyana, I; Ndeezi, G; Aceng, JR; Ware, RE. Operational analysis of the national sickle cell screening programme in the Republic of Uganda. African Journal of Laboratory Medicine. 2021; 10.

Quinn, CT; Niss, O; Dong, M; Pfeiffer, A; Korpik, J; Reynaud, M; Bonar, H; Kalfa, TA; Smart, LR; Malik, P; et al. Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemia. British Journal of Haematology. 2021; 194:617-625.

Davis, G; York, AJ; Bacon, WC; Lin, SC; McNeal, MM; Yarawsky, AE; Maciag, JJ; Miller, JL C; Locker, KC S; Bailey, M; et al. Seroprevalence of SARS-CoV-2 infection in Cincinnati Ohio USA from August to December 2020. PLoS ONE. 2021; 16.

Ware, RE; Dertinger, SD. Absence of hydroxyurea-induced mutational effects supports higher utilisation for the treatment of sickle cell anaemia. British Journal of Haematology. 2021; 194:252-266.

Smart, LR; Ware, RE. Newborn screening for sickle cell disease in sub-Saharan Africa: Is the glass half-full yet?. Pediatric Blood and Cancer. 2021; 68.

Tegha, G; Topazian, HM; Kamthunzi, P; Howard, T; Tembo, Z; Mvalo, T; Chome, N; Kumwenda, W; Mkochi, T; Hernandez, A; et al. Prospective Newborn Screening for Sickle Cell Disease and Other Inherited Blood Disorders in Central Malawi. Sozial- und Praventivmedizin. 2021; 66.

Karkoska, K; Todd, K; Niss, O; Clapp, K; Fenchel, L; Kalfa, TA; Malik, P; Quinn, CT; Ware, RE; McGann, PT. Implementation of near-universal hydroxyurea uptake among children with sickle cell anemia: A single-center experience. Pediatric Blood and Cancer. 2021; 68.

Hood, AM; Strong, H; Nwankwo, C; Johnson, Y; Peugh, J; Mara, CA; Shook, LM; Brinkman, WB; Real, FJ; Klein, MD; et al. Engaging Caregivers and Providers of Children With Sickle Cell Anemia in Shared Decision Making for Hydroxyurea: Protocol for a Multicenter Randomized Controlled Trial. JMIR Research Protocols. 2021; 10.

Boucher, AA; Dong, M; Vinks, AA; Marahatta, A; Howard, TA; Ware, RE; Nathan, JD; Abu-El-Haija, M; Luchtman-Jones, L. Hydroxyurea Pharmacokinetics in Pediatric Patients After Total Pancreatectomy With Islet Autotransplantation. Journal of Clinical Pharmacology. 2021; 61:547-554.

Sadaf, A; Seu, KG; Thaman, E; Fessler, R; Konstantinidis, DG; Bonar, HA; Korpik, J; Ware, RE; McGann, PT; Quinn, CT; et al. Automated Oxygen Gradient Ektacytometry: A Novel Biomarker in Sickle Cell Anemia. Frontiers in Physiology. 2021; 12.

Ware, RE; Dertinger, SD. There's safety in numbers. Blood. 2021; 137:729-731.

Hernandez, AG; Kiyaga, C; Howard, TA; Ssewanyana, I; Ndeezi, G; Aceng, JR; Ware, RE. Trends in sickle cell trait and disease screening in the Republic of Uganda, 2014-2019. Tropical Medicine and International Health. 2021; 26:23-32.

Cazelles, R; Shukla, RP; Ware, RE; Vinks, AA; Ben-Yoav, H. Electrochemical Determination of Hydroxyurea in a Complex Biological Matrix Using MoS2-Modified Electrodes and Chemometrics. Biomedicines. 2021; 9.

Perez-Plazola, MS; Tyburski, EA; Smart, LR; Howard, TA; Pfeiffer, A; Ware, RE; Lam, WA; McGann, PT. AnemoCheck-LRS: an optimized, color-based point-of-care test to identify severe anemia in limited-resource settings. BMC Medicine. 2020; 18.

Ambrose, EE; Smart, LR; Charles, M; Hernandez, AG; Latham, T; Hokororo, A; Beyanga, M; Howard, TA; Kamugisha, E; McElhinney, KE; et al. Surveillance for sickle cell disease, United Republic of Tanzania. Bulletin of the World Health Organization. 2020; 98:859-868.

Sadaf, A; Quinn, CT; Korpik, JB; Pfeiffer, A; Reynaud, M; Niss, O; Malik, P; Ware, RE; Kalfa, TA; McGann, PT. Rapid and Automated Quantitation of Dense Red Blood Cells: A Robust Biomarker of Therapeutic Response to Early Initiation of Hydroxyurea in Young Children with Sickle Cell Anemia. Blood. 2020; 136:16-17.

Marahatta, A; Flanagan, JM; Howard, TA; Mortier, N; Schultz, W; McElhinney, KL; Tshilolo, L; Williams, TN; Olupot-Olupot, P; Santos, B; et al. Genetic Variants That Influence Fetal Hemoglobin Expression from Hydroxyurea Treatment. Blood. 2020; 136:8-9.

Marahatta, A; Howard, TA; Stuber, SE; McElhinney, KL; Tshilolo, L; Williams, TN; Olupot-Olupot, P; Santos, B; John, CC; Opoka, R; et al. Novel Genetic Loci That Influence Fetal Hemoglobin Expression in Children with Sickle Cell Anemia. Blood. 2020; 136:33-34.

George, A; Dinu, B; Estrada, N; Minard, CG; Hurwitz, R; Mahoney, DH; Yates, AM; Vaughan, M; Carmouche, A; Airewele, G; et al. Novel dose escalation to predict treatment with hydroxyurea (NDEPTH): A randomized controlled trial of a dose-prediction equation to determine maximum tolerated dose of hydroxyurea in pediatric sickle cell disease. American Journal of Hematology. 2020; 95:E242-E244.

Ware, RE; Marahatta, A; Ware, JL; McElhinney, K; Dong, M; Vinks, AA. Hydroxyurea Exposure in Lactation: a Pharmacokinetics Study (HELPS). Journal of Pediatrics. 2020; 222:236-239.

Macharia, AW; Mochamah, G; Uyoga, S; Ndila, CM; Nyutu, G; Tendwa, M; Nyatichi, E; Makale, J; Ware, RE; Williams, TN. β-Thalassemia pathogenic variants in a cohort of children from the East African coast. Molecular genetics & genomic medicine. 2020; 8.

Jr, TB L; Lloyd-Puryear, MA; Ohene-Frempong, K; Ware, RE; Padilla, CD; Ambrose, EE; Barkat, A; Ghazal, H; Kiyaga, C; Mvalo, T; et al. Empowering newborn screening programs in African countries through establishment of an international collaborative effort. Journal of Community Genetics. 2020; 11:253-268.

John, CC; Opoka, RO; Latham, TS; Hume, HA; Nabaggala, C; Kasirye, P; Ndugwa, CM; Lane, A; Ware, RE. Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa. New England Journal of Medicine. 2020; 382:2524-2533.

Power-Hays, A; Ware, RE. Effective use of hydroxyurea for sickle cell anemia in low-resource countries. Current Opinion in Hematology. 2020; 27:172-180.

Hood, AM; McTate, EA; Joffe, NE; Crosby, LE. Sickle Cell Disease. Clinical Handbook of Psychological Consultation in Pediatric Medical Settings. 2020.

Carman, AS; Sautter, C; Anyanwu, JN; Ssemata, AS; Opoka, RO; Ware, RE; Rujumba, J; John, CC. Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood and Cancer. 2020; 67.

Datta, D; Namazzi, R; Conroy, AL; Cusick, SE; Hume, HA; Tagoola, A; Ware, RE; Opoka, RO; John, CC. Zinc for Infection Prevention in Sickle Cell Anemia (ZIPS): study protocol for a randomized placebo-controlled trial in Ugandan children with sickle cell anemia. Trials. 2019; 20.

Boucher, AA; Dong, M; Marahatta, A; Hausfeld, A; Howard, TA; Nathan, JD; Vinks, AA; McGann, PT; Ware, RE; Luchtman-Jones, L. Hydroxyurea Pharmacokinetic Profiles in Children Treated for Extreme Thrombocytosis after Total Pancreatectomy with Islet Cell Autotransplant Demonstrate Poor Absorption. Blood. 2019; 134:4893-4893.

Smart, LR; Ambrose, EE; Charles, M; Hernandez, AG; Latham, TS; Hokororo, A; Beyanga, M; Kamugisha, E; Tebuka, E; Howard, TA; et al. Genetic Analysis in the Tanzania Sickle Surveillance Study (TS3): Modifiers of Sickle Cell Disease and Identification of Hemoglobin Variants. Blood. 2019; 134:988-988.

Henrici, RC; Sautter, C; Opoka, R; Namazzi, R; Park, GS; John, D; Conroy, AL; Ware, RE; John, CC. Profound Alteration of Host Response in Severe Malarial Anemia By Sickle Cell Disease: Reduction of Parasite Sequestration and Inflammation, Upregulation of Angiopoietin-2. Blood. 2019; 134:2283-2283.

George, A; Dinu, B; Estrada, N; Minard, C; Hurwitz, RL; Mahoney, D; Yates, AM; Vaughan, M; Carmouche, A; Airewele, G; et al. Ndepth: A Randomized Controlled Trial of a Novel Dose-Prediction Equation to Determine Maximum Tolerated Dose for Hydroxyurea Therapy in Pediatric Patients with Sickle Cell Anemia. Blood. 2019; 134:2267-2267.

Ware, RE; Brown, C; de Montalembert, M; Tonda, M; Tong, B; Hoppe, C; Lehrer-Graiwer, J; Abboud, MR. Concomitant Hydroxyurea and Voxelotor: Results from the HOPE Study. Blood. 2019; 134:1003-1003.

Ware, RE; Odame, I. Newborn Screening With Sickle Cell Point of Care: A Valuable Resource in Low-Income Settings. Pediatrics. 2019; 144.

Vichinsky, E; Hoppe, CC; Ataga, KI; Ware, RE; Nduba, V; El-Beshlawy, A; Hassab, H; Achebe, MM; Alkindi, S; Brown, RC; et al. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. New England Journal of Medicine. 2019; 381:509-519.

Ware, RE; McGann, PT; Quinn, CT. Hydroxyurea for children with sickle cell anemia: Prescribe it early and often. Pediatric Blood and Cancer. 2019; 66.

McGann, PT; Niss, O; Dong, M; Marahatta, A; Howard, TA; Mizuno, T; Lane, A; Kalfa, TA; Malik, P; Quinn, CT; et al. Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia. American Journal of Hematology. 2019; 94:871-879.

Kiyaga, C; Hernandez, AG; Ssewanyana, I; Schaefer, BA; McElhinney, KE; Ndeezi, G; Howard, TA; Ndugwa, CM; Ware, RE; Aceng, JR. Sickle cell screening in Uganda: High burden, human immunodeficiency virus comorbidity, and genetic modifiers. Pediatric Blood and Cancer. 2019; 66.

Yates, AM; Joshi, VM; Aygun, B; Moen, J; Smeltzer, MP; Govindaswamy, D; Dowdy, J; Cotton, A; Kang, G; Ware, RE; et al. Elevated tricuspid regurgitation velocity in congenital hemolytic anemias: Prevalence and laboratory correlates. Pediatric Blood and Cancer. 2019; 66.

Grace, RF; Ware, RE. Pediatric Hematology. Hematology/Oncology Clinics of North America. 2019; 33:xiii-xiv.

Vichinsky, E; Hoppe, CC; Ataga, KI; Ware, RE; Nduba, V; El Beshlawy, A; Hassab, H; Achebe, MM; Al-Kindi, S; Brown, C; et al. S147 RESULTS FROM THE RANDOMIZED PLACEBO-CONTROLLED PHASE 3 HOPE TRIAL OF VOXELOTOR IN ADULTS AND ADOLESCENTS WITH SICKLE CELL DISEASE. HemaSphere. 2019; 3:25-26.

Grace, RF; Ware, RE. Pediatric Hematology. Hematology/Oncology Clinics of North America. 2019; 33.

Ware, RE; Thornburg, CD. Your tired, your poor, your huddled masses. Blood. 2019; 133:2010-2011.

Santos, B; Bernardino, L; Luis, J; da Fonseca, R; Nassesa, L; Andre, DA D O; Cuhna, L; Bengui, AF; de Oliveira, V; Tshilolo, L; et al. Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa. New England Journal of Medicine. 2019; 380:121-131.

Crosby, LE; Walton, A; Shook, LM; Ware, RE; Treadwell, M; Saving, KL; Britto, M; Peugh, J; McTate, E; Oyeku, S; et al. Development of a Hydroxyurea Decision Aid for Parents of Children With Sickle Cell Anemia. Journal of Pediatric Hematology/Oncology. 2019; 41:56-63.

Kiyaga, C; Hernandez, AG; Ssewanyana, I; McElhinney, KE; Ndeezi, G; Howard, TA; Ndugwa, CM; Ware, RE; Aceng, JR. Building a sickle cell disease screening program in the Republic of Uganda: the Uganda Sickle Surveillance Study (US3) with 3 years of follow-up screening results. Blood Advances. 2018; 2:4-7.

Parker, CJ; Ware, RE. Paroxysmal nocturnal hemoglobinuria. Wintrobe's Clinical Hematology: Fourteenth Edition. 2018.

Shook, LM; Ware, RE. Sickle cell screening in Europe: the time has come. British Journal of Haematology. 2018; 183:534-535.

McGann, PT; Williams, AM; Ellis, G; McElhinney, KE; Romano, L; Woodall, J; Howard, TA; Tegha, G; Krysiak, R; Lark, RM; et al. Prevalence of inherited blood disorders and associations with malaria and anemia in Malawian children. Blood Advances. 2018; 2:3035-3044.

Rotz, SJ; Ware, RE; Kumar, A. Diagnosis and management of chronic and refractory immune cytopenias in children, adolescents, and young adults. Pediatric Blood and Cancer. 2018; 65.

McGann, PT; Williams, TN; Olupot-Olupot, P; Tomlinson, GA; Lane, A; Reis da Fonseca, JL; Kitenge, R; Mochamah, G; Wabwire, H; Stuber, S; et al. Realizing effectiveness across continents with hydroxyurea: Enrollment and baseline characteristics of the multicenter REACH study in Sub-Saharan Africa. American Journal of Hematology. 2018; 93:537-545.

Shook, LM; Ware, RE. Effective screening leads to better outcomes in sickle cell disease. Archives of Disease in Childhood. 2018; 103:628-630.

Dong, M; McGann, PT; Mizuno, T; Ware, RE; Vinks, AA. Model-based dosing with concentration feedback as an integral part of personalized hydroxycarbamide management. British Journal of Clinical Pharmacology. 2018; 84:1410-1412.

Thornburg, CD; Ware, RE. Children with sickle cell disease migrating to the United States from sub-Saharan Africa. Pediatric Blood and Cancer. 2018; 65.

Ware, RE; Niss, O. Treatment of Autoimmune Hemolytic Anemia. Immune Hematology. 2018.

Smart, LR; Hernandez, AG; Ware, RE. Sickle cell disease: Translating clinical care to low-resource countries through international research collaborations. Seminars in Hematology. 2018; 55:102-112.

Rankine-Mullings, AE; Morrison-Levy, N; Soares, D; Aldred, K; King, L; Ali, S; Knight-Madden, JM; Wisdom-Phipps, M; Adams, RJ; Ware, RE; et al. Transcranial Doppler velocity among Jamaican children with sickle cell anaemia: determining the significance of haematological values and nutrition. British Journal of Haematology. 2018; 181:242-251.

Smart, LR; Ambrose, EE; Raphael, KC; Hokororo, A; Kamugisha, E; Tyburski, EA; Lam, WA; Ware, RE; McGann, PT. Simultaneous point-of-care detection of anemia and sickle cell disease in Tanzania: the RAPID study. Annals of Hematology. 2018; 97:239-246.